Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy.
Journal Information
Full Title: Exp Hematol Oncol
Abbreviation: Exp Hematol Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateThis research was approved by the ethical committee in the Institute of Hematology and Blood Diseases Hospital, and all procedures were in accordance with the Helsinki Declaration. Written informed consent was obtained from each participant. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."
"Funding This work was supported by the National Key Research and Development Program of China (2019YFA0110200), National Natural Science Foundation of China (81830005) and CAMS Innovation Fund for Medical Sciences (2021-I2M-1-041)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025